OR WAIT null SECS
July 28, 2015.
Companies are exploring new markets for innovative assets to add value to their pipeline, according to analysis from Frost & Sullivan. The company's report Funding Patterns in the Global Pharma and Biotech Industry reveals the volume of venture capital (VC) deals fell by 41.2 percent between 2010 and 2014, while private equity (PE) deal volume declined by 23.4 percent. However, it states, investors will become established within the pharmaceutical and biotech industry to avail long-term returns. Frost & Sullivan Senior Research Analyst Saneesh Edacherian says that corporate investors "expect to play a significant role in intensifying competition and replenishing the depleting drug pipeline." He adds that the "strong return of the initial public offering market in the U.S. is likely to further encourage PE/VC investors, especially in the biotechnology sector.” For more on this report, visit http://corpcom.frost.com/forms/EU_PR_AZanchi_NF54-F1_28July15